<DOC>
	<DOCNO>NCT00531817</DOCNO>
	<brief_summary>This 2-arm study assess safety efficacy tocilizumab versus placebo , combination disease modify antirheumatic drug ( DMARDs ) , regard reduction sign symptom , patient moderate severe active rheumatoid arthritis inadequate response DMARDs . Patients randomize ratio 2:1 receive either tocilizumab 8 mg/kg intravenously ( IV ) placebo IV every 4 week . All patient also receive stable antirheumatic therapy , include permitted DMARDs . The anticipated time study treatment 3-12 month target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Tocilizumab Combination With DMARDs Patients With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Adult patient , â‰¥18 year age Active rheumatoid arthritis &gt; 6 month duration Received permit DMARDs stable dose least 7 week prior baseline Rheumatic autoimmune disease inflammatory joint disease rheumatoid arthritis Major surgery within 8 week prior screen plan within 6 month follow randomization Unsuccessful treatment biologic agent , include antiTNF agent Previous treatment tocilizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>